Actuate Therapeutics (ACTU) Profit After Tax (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Profit After Tax of -$4.6 million for Q4 2025, up 29.35% year-over-year from -$3.5 million in Q4 2024, and up 15.78% quarter-over-quarter from -$5.4 million in Q3 2025.
Actuate Therapeutics (ACTU) Profit After Tax (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Profit After Tax for 3 consecutive years, with -$4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 29.35% year-over-year to -$4.6 million; the TTM figure through Dec 2025 stood at -$22.2 million (up 18.54% YoY), while the FY2025 annual figure was -$22.2 million, up 18.54% from the prior year.
- Profit After Tax advanced to -$4.6 million in Q4 2025 per ACTU's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$4.6 million in Q4 2025 and bottomed at -$8.3 million in Q1 2024.
- Historically, Profit After Tax has averaged -$6.3 million across 3 years, with a median of -$6.3 million in 2025.
- Annual changes were most pronounced in 2024 — Profit After Tax decreased 18.97% — and 2025, when it grew 29.35%.
- Actuate Therapeutics' Profit After Tax stood at -$7.6 million in 2023, then increased by 15.32% to -$6.4 million in 2024, then advanced by 29.35% to -$4.6 million in 2025.
- Business Quant data shows ACTU's Profit After Tax at -$4.6 million in Q4 2025, -$5.4 million in Q3 2025, and -$5.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | -4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.55 Mn |
| Sep 30, 2025 | -5.41 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | -6.32 Mn |
| Dec 31, 2024 | -6.45 Mn |
| Sep 30, 2024 | -5.97 Mn |
| Jun 30, 2024 | -6.57 Mn |
| Mar 31, 2024 | -8.30 Mn |
| Dec 31, 2023 | -7.61 Mn |
| Sep 30, 2023 | -6.34 Mn |
| Jun 30, 2023 | -5.52 Mn |